Bivalirudin: a new generation antithrombotic drug.

Article Details

Citation

Copy to clipboard

Scatena R

Bivalirudin: a new generation antithrombotic drug.

Expert Opin Investig Drugs. 2000 May;9(5):1119-27.

PubMed ID

11060732 [ View in PubMed

]

Abstract

Bivalirudin (Angiomax, The Medicines Company) is a synthetic 20 amino acid peptide rationally designed on the basis of structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin represents a new class of anticoagulant drugs that directly inhibits thrombin, a key component in blood clot formation and extension. With its high binding affinity and specificity for thrombin, bivalirudin acts directly on thrombin, rather than via other clotting factors. The compound has a variety of potential uses as an alternative to heparin in the management of cardiovascular disease and related medical procedures i.e., unstable angina (UA), myocardial infarction (MI) and percutaneous transluminal coronary angioplasty (PTCA).

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Bivalirudin	Prothrombin	Protein	Humans	Yes	Inhibitor	Details